{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-23-000219","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.394818+00:00","generated_at":"2026-06-12T03:12:03.031508+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Lilly Q2 revenue $8.31B (+28%), EPS $1.95 (+86%), raises FY guidance","bullets":["Q2 revenue $8,312M, up 28% YoY; reported EPS $1.95 (+86%); non-GAAP EPS $2.11 (+69%, includes $0.43 from Baqsimi rights sale).","FY 2023 reported EPS guidance raised to $9.20-$9.40; non-GAAP EPS raised to $9.70-$9.90, up $1.02 and $1.05 respectively.","Mounjaro led New Products with $1.00B revenue; Growth Products up 16% to $4.93B, led by Verzenio, Jardiance, Taltz.","Pipeline progress: donanemab submitted to FDA/EMA for Alzheimer's; tirzepatide submitted for chronic weight management; mirikizumab approved in EU.","Announced agreements to acquire DICE Therapeutics, Sigilon Therapeutics, and Versanis Bio to expand autoimmune and cardiometabolic pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-23-000219","json":"https://secwatch.observer/filing/0000059478-23-000219.json","markdown":"https://secwatch.observer/filing/0000059478-23-000219.md","text":"https://secwatch.observer/filing/0000059478-23-000219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000219/0000059478-23-000219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000219/lly-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:12:03.031508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07f1a6ceee57860c25068e1b8dc21070b0ee1739","claim":"ELI LILLY & Co reported the second quarter of 2023 results: revenue $8,312.1, net income $1,763.2, EPS $1.95. Guidance raised.","evidence_excerpt":"on important public announcements, visit the news section of Lilly's website. 2 Financial Results $ in millions, except per share data Second Quarter 2023 2022 % Change Revenue $8,312.1 $6,488.0 28% Net Income – Reported 1,763.2 952.5 85% EPS – Reported 1.95 1.05 86% Net Income – Non-GAAP 1,904.4 1,131.3 68% EPS – Non-GAAP 2.11 1.25 69% A discussion of the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/59478/000005947823000219/0000059478-23-000219-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter of 2023"},{"label":"Revenue","value":"$8,312.1"},{"label":"Net income","value":"$1,763.2"},{"label":"EPS","value":"$1.95"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}